You are here

MSC Treatment of COPD

Mesenchymal stem cell (MSC) therapy represents an emerging approach to the relief of chronic inflammation. As part of a phase I clinical study, researchers led by Yuben P. Moodley (University of Western Australia, Perth, WA, Australia) report, for the first time, that MSCs modulate critical pathological pathways that drive inflammation in patients with chronic obstructive pulmonary disease (COPD). This new STEM CELLS Translational Medicine article provides novel insights that may guide the development of MSC therapy as a treatment option for patients with chronic airway diseases.